Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 3/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.46 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3121822 | 0.95 | CHRNA3 (0.41) | CHRNA3CHRNB4KRASCHRNB2CHRNA4 | |
| SCHEMBL7055867 | 0.92 | CHRNB4 (0.53) | CHRNA3CHRNB4KRASCHRNB2CHRNA4 | |
| SCHEMBL906007 | 0.92 | CHRNB4 (0.53) | CHRNA3CHRNB4KRASCHRNB2CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL3116407 | 0.88 | IRAK4 (0.38) | CHRNA3CHRNB4CHRNB2CHRNA4CHRNB3 | |
| SCHEMBL3111253 | 0.86 | CHRNB4 (0.47) | CHRNA3CHRNB4KRASCHRNB2CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL3124283 | 0.84 | HTR2C (0.40) | HTR2AHTR2CKCNH2SSTR4SSTR1 | |
| Trifluoroacetic Acid SCHEMBL6198900 | 0.84 | HTR2C (0.39) | HTR2AHTR2CKCNH2SSTR4SSTR1 | |
| SCHEMBL906053 | 0.79 | SYK (0.39) | CHRNA3CHRNB4HTR2AHTR2CKCNH2 | |
| Succinic Acid SCHEMBL15022004 | 0.78 | HTR2C (0.39) | HTR2AHTR2CKCNH2SSTR4SSTR1 | |
| SCHEMBL906026 | 0.78 | HTR2C (0.42) | CHRNB2CHRNA4HTR2AHTR2CKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513831-B1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB PUBL (SE) | 2010-01-06 | — | — | EP | claimed |
| EP-1513831-B1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB PUBL (SE) | 2010-01-06 | — | — | EP | disclosed |
| US-7226925-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2007-06-05 | — | — | US | disclosed |
| US-20040029888-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029888-A1 | Novel compounds, their use and preparation | TPH1, TPH2, HTR1A | CHRNA3 182/4885CHRNB4 115/4885KRAS 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.